-
1
New method developed for NK cell mass production from stem cells.
-
2
Process includes expansion of CD34+ stem cells and differentiation via organoid systems.
-
3
Yields of ~14 million NK cells per stem cell achieved.
-
4
Dramatic reduction in viral vector needs (up to 600,000-fold).
-
5
Effective at suppressing tumor growth in leukemia models.
-
6
Potential for cost-effective 'off-the-shelf' immunotherapies.
-
7
CAR-NK cells retain potency post-cryopreservation.
Original Source(s)
Related Content
Early Results From a Trial of Active Surveillance for Low-Risk DCIS are ‘Reassuring,’ Say Researchers
“For women with low-risk DCIS, these interim results are reassuring. There is currently no indication that active surveillance leads to worse early outcomes compared with immediate surgery. It’s impor...
April 1, 2026
-
4 min
Could Mass Spec Overcome the CAR T Solid Tumor Barrier?
Joey Sheff explains how proteomics is revealing targets, guiding CAR design, and predicting function in solid tumors.
April 1, 2026
-
8 min
AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC
An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-...
by Lisa Astor
April 1, 2026
-
5 min
